The therapy claims to be the first therapeutic agent to utilise molecularly defined biomarkers for precision-targeted HCC ...

Hepatocellular carcinoma is a cancer that starts in your ... In more advanced cases it can’t be cured, but treatment and support can help you live longer and better. It's important to remember ...

First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib ...

Ultrasound (US) technology has significantly advanced and plays a pivotal role in the surveillance, diagnosis, and treatment of HCC. This paper delves into various ultrasound techniques and their ...

Professor Park Joong-won of the Department of Gastroenterology at Myongji Hospital announced that the combination treatment ...

China NMPA grants breakthrough therapy designation to Abbisko Therapeutics’ irpagratinib to treat hepatocellular carcinoma: Shanghai Tuesday, May 27, 2025, 10:00 Hrs [IST] Abbis ...

Abbisko Therapeutics (HKEX Code: 02256) announced that its self-developed, highly selective small molecule FGFR4 inhibitor, irpagratinib (ABSK011), has received approval of Breakthrough Therapy ...

Development of targeted therapies against FGFR4 represent an innovative and novel approach to the treatment of HCC. To date, no FGFR4 inhibitor has been granted regulatory approval globally.

The extensive exploration of combination therapies involving cadonilimab for HCC is expected to offer more effective treatment options for both early-stage and advanced HCC patients. HCC is one of ...

The study aimed to evaluate the efficacy and safety of toripalimab in combination with bevacizumab for the first-line treatment of unresectable or metastatic HCC compared to the standard treatment ...

Irpagratinib is the first therapeutic agent to leverage molecularly defined biomarkers for precision-targeted treatment in patients with HCC. During clinical trials, innovative drugs or modified ...